Heart Failure - Pipeline Review, H1 2012

Heart Failure – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Heart Failure - Pipeline Review, H1 2012', provides an overview of the Heart Failure therapeutic pipeline. This report provides information on the therapeutic development for Heart Failure, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Heart Failure. 'Heart Failure - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Heart Failure.
- A review of the Heart Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Heart Failure pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Heart Failure.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Heart Failure pipeline depth and focus of Heart Failure therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Heart Failure Therapeutic Products under Development, Key Players in Heart Failure Therapeutics, Heart Failure Pipeline Overview, Heart Failure Pipeline, Heart Failure Pipeline Assessment SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Heart Failure Overview
Therapeutics Development
An Overview of Pipeline Products for Heart Failure
Heart Failure Therapeutics under Development by Companies
Heart Failure Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Heart Failure Therapeutics – Products under Development by Companies
Heart Failure Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Heart Failure Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
GlaxoSmithKline plc
Aldagen, Inc.
Novartis AG
Acorda Therapeutics, Inc.
Les Laboratoires Servier
Sigma-Tau S.p.A.
Bayer AG
Celladon Corporation
Mesoblast Ltd
Nile Therapeutics, Inc.
Cardio3 BioSciences SA
Cytokinetics, Inc
POZEN Inc.
Torrent Pharmaceuticals Limited
MetrioPharm AG
AcelleRX Therapeutics Inc.
Trevena, Inc.
Cardioxyl Pharmaceuticals, Inc.
ARCA biopharma, Inc.
Cornerstone Therapeutics Inc.
Medistem, Inc.
Pharis Biotec GmbH
miRagen Therapeutics, Inc.
Sihuan Pharmaceutical Holdings Group Ltd.
MicroDose Therapeutx, Inc.
Corimmun GmbH
Heart Failure – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Darapladib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ularitide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LCZ696 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALD-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Omecamtiv Mecarbil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Albiglutide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PA32540 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CD-NP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CD-NP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Istaroxime - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mydicar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CXL-1020 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HMGB1 Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Furosemide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JVS-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-Cure - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Spironolactone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Perhexiline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clenbuterol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Levosimendan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous hCSC Injection - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRV027 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Human Mesenchymal Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Human Bone Marrow Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mesenchymal Stromal Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bone Marrow Derived Adult Stem Cells + G-CSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Revascor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nesiritide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Levosimendan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Octagam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anakinra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sildenafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Omacor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aliskiren - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-39588146 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
G-CSF + Autologous Bone Marrow Progenitor Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AGE Breaker - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hydralazine + Amlodipine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Spironolactone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Estrogen Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nalmefene Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Heart Failure Therapeutics – Drug Profile Updates
Heart Failure Therapeutics – Discontinued Products
Heart Failure Therapeutics - Dormant Products
Heart Failure – Product Development Milestones
Featured News & Press Releases
Mar 28, 2012: Nile Therapeutics Announces Positive Phase I Trial Results Of Cenderitide In Patients With Chronic Heart Failure
Mar 15, 2012: Cytomedix Announces Publication Of Positive Phase I Clinical Data Of ALD-201 In American Heart Journal
Mar 14, 2012: Forest And Janssen File Lawsuits Against Several Companies For Infringement Of BYSTOLIC Patent
Mar 14, 2012: Nile Therapeutics To Present Clinical Data Of Cenderitide At American College Of Cardiology Annual Scientific Meeting
Mar 14, 2012: BioCardia And Juventas Announce Phase II Development Program Of JVS-100 Delivered With Helical Infusion System To Treat Heart Failure
Feb 21, 2012: Cytokinetics Announces Initiation Of Phase I Clinical Trial Of Oral Formulations Of Omecamtiv Mecarbil In Healthy Volunteers
Feb 15, 2012: ROVI's Corlentor Receives EMA Approval For Use In Heart Failure
Jan 30, 2012: Medistem And ERCell Initiate Phase II RECOVER-ERC Heart Failure Trial
Jan 30, 2012: Juventas Therapeutics Reports One Year Data From Phase I Heart Failure Clinical Trial
Jan 10, 2012: Cardio3 BioSciences Secures Additional €3.1m In Non-dilutive Funding From Walloon Region And European Commission
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Heart Failure, H1 2012
Products under Development for Heart Failure – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Bristol-Myers Squibb Company, H1 2012
Johnson & Johnson, H1 2012
GlaxoSmithKline plc, H1 2012
Aldagen, Inc., H1 2012
Novartis AG, H1 2012
Acorda Therapeutics, Inc., H1 2012
Les Laboratoires Servier, H1 2012
Sigma-Tau S.p.A., H1 2012
Bayer AG, H1 2012
Celladon Corporation, H1 2012
Mesoblast Ltd, H1 2012
Nile Therapeutics, Inc., H1 2012
Cardio3 BioSciences SA, H1 2012
Cytokinetics, Inc, H1 2012
POZEN Inc., H1 2012
Torrent Pharmaceuticals Limited, H1 2012
MetrioPharm AG, H1 2012
AcelleRX Therapeutics Inc., H1 2012
Trevena, Inc., H1 2012
Cardioxyl Pharmaceuticals, Inc., H1 2012
ARCA biopharma, Inc., H1 2012
Cornerstone Therapeutics Inc., H1 2012
Medistem, Inc., H1 2012
Pharis Biotec GmbH, H1 2012
miRagen Therapeutics, Inc., H1 2012
Sihuan Pharmaceutical Holdings Group Ltd., H1 2012
MicroDose Therapeutx, Inc., H1 2012
Corimmun GmbH, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Heart Failure Therapeutics – Drug Profile Updates
Heart Failure Therapeutics – Discontinued Products
Heart Failure Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Heart Failure, H1 2012
Products under Development for Heart Failure – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012